| Year |
Citation |
Score |
| 2024 |
Beshiri ML, Capaldo BJ, Lake R, Ku AT, Burner D, Tice CM, Tran C, Kostas J, Alilin AN, Yin JJ, Agarwal S, Morris SA, Karzai FH, Lotan TL, Dahut WL, ... Sowalsky AG, et al. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer. Stem Cells (Dayton, Ohio). PMID 38563224 DOI: 10.1093/stmcls/sxae025 |
0.337 |
|
| 2024 |
Wilkinson S, Ku AT, Lis RT, King IM, Low D, Trostel SY, Bright JR, Terrigino NT, Baj A, Fenimore JM, Li C, Vo B, Jansen CS, Ye H, Whitlock NC, ... ... Sowalsky AG, et al. Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition. Medrxiv : the Preprint Server For Health Sciences. PMID 38370835 DOI: 10.1101/2024.02.09.24302395 |
0.486 |
|
| 2024 |
Poluben L, Nouri M, Liang J, Varkaris A, Ersoy-Fazlioglu B, Voznesensky O, Lee II, Qiu X, Cato L, Seo JH, Freedman ML, Sowalsky AG, Lack NA, Corey E, Nelson PS, et al. Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 38260576 DOI: 10.1101/2024.01.10.575110 |
0.317 |
|
| 2023 |
Dairo OO, DePaula Oliveira L, Schaffer E, Vidotto T, Mendes AAA, Lu J, Huynh SV, Hicks JL, Sowalsky AG, De Marzo AM, Joshu CE, Hanratty B, Sfanos KS, Isaacs WB, Haffner MC, et al. FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-Genomic Features of Prostate Cancer. Cancer Research Communications. PMID 38112617 DOI: 10.1158/2767-9764.CRC-23-0248 |
0.448 |
|
| 2023 |
Wilkinson S, Sowalsky AG. Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy. Journal of the National Cancer Institute. PMID 37816132 DOI: 10.1093/jnci/djad192 |
0.364 |
|
| 2023 |
Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit RF, Coleman I, Lee JK, Nelson PS, Capaldo BJ, ... ... Sowalsky AG, et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. The Journal of Clinical Investigation. PMID 37725435 DOI: 10.1172/JCI162148 |
0.402 |
|
| 2023 |
Ku AT, Shankavaram U, Trostel SY, Zhang H, Sater HA, Harmon SA, Carrabba NV, Liu Y, Wood BJ, Pinto PA, Choyke PL, Stoyanova R, Davicioni E, Pollack A, Turkbey B, ... Sowalsky AG, et al. Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence. Medrxiv : the Preprint Server For Health Sciences. PMID 37205576 DOI: 10.1101/2023.05.01.23288883 |
0.426 |
|
| 2022 |
Germanos AA, Arora S, Zheng Y, Goddard ET, Coleman IM, Ku AT, Wilkinson S, Song H, Brady NJ, Amezquita RA, Zager M, Long A, Yang YC, Bielas JH, Gottardo R, ... ... Sowalsky AG, et al. Defining cellular population dynamics at single-cell resolution during prostate cancer progression. Elife. 11. PMID 36511483 DOI: 10.7554/eLife.79076 |
0.464 |
|
| 2022 |
Whitlock NC, White ME, Capaldo BJ, Ku AT, Agarwal S, Fang L, Wilkinson S, Trostel SY, Shi ZD, Basuli F, Wong K, Jagoda EM, Kelly K, Choyke PL, Sowalsky AG. Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A. Discover. Oncology. 13: 97. PMID 36181613 DOI: 10.1007/s12672-022-00565-3 |
0.416 |
|
| 2022 |
Takeda DY, Sowalsky AG. Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis. Cancer Cell. 40: 1086-1088. PMID 36179684 DOI: 10.1016/j.ccell.2022.09.002 |
0.392 |
|
| 2022 |
Sowalsky AG, Plymate SR, Haffner MC, de Bono JS, Sharp A. Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer: AR-V7 is Rare in Hormone-sensitive Prostate Cancer. European Urology. PMID 36038450 DOI: 10.1016/j.eururo.2022.06.028 |
0.376 |
|
| 2022 |
Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, et al. Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35695870 DOI: 10.1158/1078-0432.CCR-22-0851 |
0.391 |
|
| 2022 |
Bright JR, Lis RT, Ku AT, Terrigino NT, Whitlock NC, Trostel SY, Carrabba NV, Harmon SA, Turkbey B, Wilkinson S, Sowalsky AG. PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 35227084 DOI: 10.1097/JU.0000000000002492 |
0.405 |
|
| 2022 |
Dong X, Xue H, Mo F, Lin YY, Lin D, Wong NKY, Sun Y, Wilkinson S, Ku AT, Hao J, Ci X, Wu R, Haegert A, Silver R, Taplin ME, ... ... Sowalsky AG, et al. . Molecular Cancer Research : McR. PMID 35082166 DOI: 10.1158/1541-7786.MCR-21-1037 |
0.445 |
|
| 2021 |
Guo H, Wu Y, Nouri M, Spisak S, Russo JW, Sowalsky AG, Pomerantz MM, Wei Z, Korthauer K, Seo JH, Wang L, Arai S, Freedman ML, He HH, Chen S, et al. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nature Communications. 12: 7308. PMID 34911936 DOI: 10.1038/s41467-021-27077-y |
0.325 |
|
| 2021 |
Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, Russo JW. Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. Jco Precision Oncology. 5. PMID 34568716 DOI: 10.1200/PO.21.00059 |
0.475 |
|
| 2021 |
Ku AT, Wilkinson S, Sowalsky AG. Comparison of approaches to transcriptomic analysis in multi-sampled tumors. Briefings in Bioinformatics. PMID 34415294 DOI: 10.1093/bib/bbab337 |
0.385 |
|
| 2021 |
Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, et al. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34168052 DOI: 10.1158/1078-0432.CCR-21-0121 |
0.428 |
|
| 2021 |
Wilkinson S, Ye H, Lis RT, Sowalsky AG. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate. European Urology. PMID 34148711 DOI: 10.1016/j.eururo.2021.06.002 |
0.347 |
|
| 2021 |
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, ... ... Sowalsky AG, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer. 2: 444-456. PMID 33899001 DOI: 10.1038/s43018-021-00185-w |
0.397 |
|
| 2021 |
Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, ... ... Sowalsky AG, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology. PMID 33785256 DOI: 10.1016/j.eururo.2021.03.009 |
0.367 |
|
| 2020 |
Sharad S, Allemang TC, Li H, Nousome D, Ku AT, Whitlock NC, Sowalsky AG, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Dobi A. Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers. Frontiers in Oncology. 10: 584280. PMID 33575208 DOI: 10.3389/fonc.2020.584280 |
0.425 |
|
| 2020 |
Sowalsky AG, Sharp A, Trostel SY, de Bono JS, Plymate SR. AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification. Cancer Treatment and Research Communications. 100218. PMID 33516656 DOI: 10.1016/j.ctarc.2020.100218 |
0.338 |
|
| 2020 |
Karzai F, Walker SM, Wilkinson S, Madan RA, Shih JH, Merino MJ, Harmon SA, VanderWeele DJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M, Couvillon A, ... ... Sowalsky AG, et al. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33023952 DOI: 10.1158/1078-0432.CCR-20-2344 |
0.369 |
|
| 2020 |
Wilkinson S, Sowalsky AG. Battling the two-headed dragon of prostate cancer targeted therapy. Molecular & Cellular Oncology. 7: 1745037. PMID 32944614 DOI: 10.1080/23723556.2020.1745037 |
0.481 |
|
| 2020 |
Whitlock NC, Trostel SY, Wilkinson S, Terrigino NT, Hennigan ST, Lake R, Carrabba NV, Atway R, Walton ED, Gryder BE, Capaldo BJ, Ye H, Sowalsky AG. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. Oncogene. PMID 32681068 DOI: 10.1038/S41388-020-01389-7 |
0.524 |
|
| 2020 |
Wilkinson S, Harmon SA, Terrigino NT, Karzai F, Pinto PA, Madan RA, VanderWeele DJ, Lake R, Atway R, Bright JR, Carrabba NV, Trostel SY, Lis RT, Chun G, Gulley JL, ... ... Sowalsky AG, et al. A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications. 11: 837. PMID 32054861 DOI: 10.1038/S41467-020-14657-7 |
0.531 |
|
| 2020 |
Karzai F, Madan RA, Sowalsky AG, Bilusic M, Chun G, Cordes LM, Wilkinson SC, Terrigino N, Harmon S, Pinto PA, Choyke PL, Turkbey B, Gulley JL, Dahut WL. A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures. Journal of Clinical Oncology. 38: 368-368. DOI: 10.1200/Jco.2020.38.6_Suppl.368 |
0.46 |
|
| 2020 |
Wilkinson SC, Ye H, Terrigino N, Carrabba N, Atway R, Trostel SY, Bright J, Hennigan ST, Lis R, Lake R, Harmon S, Turkbey B, Pinto PA, Choyke PL, Karzai F, ... ... Sowalsky AG, et al. Multiple primary prostate tumors with differential drug sensitivity. Journal of Clinical Oncology. 38: 342-342. DOI: 10.1200/Jco.2020.38.6_Suppl.342 |
0.556 |
|
| 2020 |
Sowalsky AG. Doubling down on tumor suppressor deletion Science Translational Medicine. 12: eaba2903. DOI: 10.1126/Scitranslmed.Aba2903 |
0.53 |
|
| 2020 |
Wilkinson S, Sowalsky AG. Battling the two-headed dragon of prostate cancer targeted therapy Molecular & Cellular Oncology. 7: 1745037. DOI: 10.1080/23723556.2020.1745037 |
0.36 |
|
| 2019 |
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, ... ... Sowalsky AG, et al. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Reports. 29: 2355-2370.e6. PMID 31747605 DOI: 10.1016/J.Celrep.2019.10.068 |
0.51 |
|
| 2019 |
Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, ... ... Sowalsky AG, et al. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. Jco Precision Oncology. 3. PMID 31528835 DOI: 10.1200/PO.19.00176 |
0.417 |
|
| 2019 |
Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, et al. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer and Prostatic Diseases. PMID 30890759 DOI: 10.1038/S41391-019-0141-6 |
0.511 |
|
| 2019 |
Karzai F, Madan RA, VanderWeele DJ, Chun G, Bilusic M, Cordes LM, Carrabba N, Wilkinson S, Ye H, Harmon S, Sowalsky AG, Turkbey B, Pinto PA, Choyke PL, Gulley JL, et al. A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI). Journal of Clinical Oncology. 37: 63-63. DOI: 10.1200/Jco.2019.37.7_Suppl.63 |
0.436 |
|
| 2019 |
Sowalsky AG, Wilkinson S, Ye H, Harmon S, Turkbey B, Carrabba N, Atway R, Chun G, VanderWeele DJ, Karzai F, Madan RA, Pinto PA, Choyke PL, Dahut WL. Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide. Journal of Clinical Oncology. 37: 61-61. DOI: 10.1200/Jco.2019.37.7_Suppl.61 |
0.48 |
|
| 2019 |
Terrigino NT, Hennigan ST, Trostel S, Wilkinson SC, Ye H, Sowalsky AG. Abstract 736: Development of an allele-specific assay for detecting circulating tumor DNA in prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-736 |
0.49 |
|
| 2019 |
Whitlock NC, Trostel S, Atway R, Walton E, Capaldo BJ, Ye H, Sowalsky AG. Abstract 2606: Genetic contribution of MYC to the development of primary prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Prca2017-B058 |
0.468 |
|
| 2019 |
Wilkinson S, Ye H, Carrabba N, Atway R, Trostel SY, Hennigan T, Lake R, Harmon S, Chun G, Turkbey B, Pinto PA, Choyke PL, Karzai F, VanderWeele DJ, Kelly K, ... ... Sowalsky AG, et al. Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer Cancer Research. 79: 2510-2510. DOI: 10.1158/1538-7445.Am2019-2510 |
0.519 |
|
| 2019 |
Sheahan A, Morel K, Burkhart D, Baca S, Labbè D, Roehle K, Calagua C, Ye H, Galbo P, Panja S, Mitrofanova A, Hamid A, Kibel A, Choudhury A, Pomerantz M, ... ... Sowalsky A, et al. Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B006 |
0.496 |
|
| 2019 |
Sowalsky AG. Following bloody footprints: Cancer diagnosis from cell-free DNA Science Translational Medicine. 11: eaaz3724. DOI: 10.1126/Scitranslmed.Aaz3724 |
0.393 |
|
| 2019 |
Sowalsky AG. TAMpering with TIME Science Translational Medicine. 11: eaaz0308. DOI: 10.1126/Scitranslmed.Aaz0308 |
0.529 |
|
| 2019 |
Sowalsky AG. SAMpling cancer development one carbon at a time Science Translational Medicine. 11: eaax2731. DOI: 10.1126/Scitranslmed.Aax2731 |
0.418 |
|
| 2019 |
Sowalsky AG. CuRBing cancer’s enthusiasm Science Translational Medicine. 11: eaax1715. DOI: 10.1126/Scitranslmed.Aax1715 |
0.377 |
|
| 2019 |
Sowalsky A, Turkbey B, Trostel S, Shankavaram U, Carrabba N, Sater H, Lake R, Rowe L, Cooley-Zgela T, Schott E, Zhang H, Pinto P, Wood B, Liu S, Davicioni E, et al. Integrated Radiogenomic Subtyping and Treatment Response of Intermediate and High Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 105: S77. DOI: 10.1016/j.ijrobp.2019.06.537 |
0.347 |
|
| 2018 |
Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, et al. A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget. 9: 37676-37688. PMID 30701023 DOI: 10.18632/Oncotarget.26481 |
0.383 |
|
| 2018 |
Carneiro A, Barbosa ÁRG, Takemura LS, Kayano PP, Moran NKS, Chen CK, Wroclawski ML, Lemos GC, da Cunha IW, Obara MT, Tobias-Machado M, Sowalsky AG, Bianco B. The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature. Frontiers in Oncology. 8: 377. PMID 30280090 DOI: 10.3389/Fonc.2018.00377 |
0.536 |
|
| 2018 |
Carneiro A, Priante Kayano P, Gomes Barbosa ÁR, Langer Wroclawski M, Ko Chen C, Cavlini GC, Reche GJ, Sanchez-Salas R, Tobias-Machado M, Sowalsky AG, Bianco B. Are localized prostate cancer biomarkers useful in the clinical practice? Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 40: 1010428318799255. PMID 30204063 DOI: 10.1177/1010428318799255 |
0.497 |
|
| 2018 |
Ye H, Sowalsky AG. Molecular correlates of intermediate- and high-risk localized prostate cancer. Urologic Oncology. 36: 368-374. PMID 30103901 DOI: 10.1016/J.Urolonc.2017.12.022 |
0.444 |
|
| 2018 |
Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Research. PMID 30012673 DOI: 10.1158/0008-5472.Can-17-3615 |
0.467 |
|
| 2018 |
Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, et al. Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations. Cancer Research. PMID 29921690 DOI: 10.1158/0008-5472.Can-18-0610 |
0.534 |
|
| 2018 |
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KA, Yin JJ, Alilin AN, Karzai FH, Dahut W, Corey E, Kelly K. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29748182 DOI: 10.1158/1078-0432.Ccr-18-0409 |
0.476 |
|
| 2018 |
Ward Y, Lake R, Faraji F, Sperger J, Martin P, Gilliard C, Ku KP, Rodems T, Niles D, Tillman H, Yin J, Hunter K, Sowalsky AG, Lang J, Kelly K. Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration. Cell Reports. 23: 808-822. PMID 29669286 DOI: 10.1016/J.Celrep.2018.03.092 |
0.352 |
|
| 2018 |
VanderWeele DJ, Turkbey B, Karzai F, Harmon S, Sowalsky AG, Ye H, Wilkinson S, Chun G, Gold S, Pinto PA, Choyke PL, Dahut WL. Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial. Journal of Clinical Oncology. 36: 94-94. DOI: 10.1200/Jco.2018.36.6_Suppl.94 |
0.442 |
|
| 2018 |
Sowalsky AG, Wilkinson S, Ye H, VanderWeele DJ, Turkbey B, Hennigan ST, Atway R, Trostel SY, Lake R, Karzai F, Harmon S, Chun G, Kelly K, Pinto PA, Choyke PL, et al. Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer. Journal of Clinical Oncology. 36: 34-34. DOI: 10.1200/Jco.2018.36.6_Suppl.34 |
0.508 |
|
| 2018 |
Carneiro A, Kayano PP, Sowalsky AG, Santos TJN, Dell'oglio P, Moran NKS, Santiago LHS, Lemos GC, Machado MT, Sanchez-Salas R, Wagner A, Bianco B. Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance. Journal of Clinical Oncology. 36: e17068-e17068. DOI: 10.1200/Jco.2018.36.15_Suppl.E17068 |
0.475 |
|
| 2018 |
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, McGowen K, Alilin AN, Yin J, Karzai FH, Dahut WL, Corey E, Kelly K. Abstract B051: PDX-derived and patient-derived prostate cancer organoids as a clinically relevant platform for translational research Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B051 |
0.501 |
|
| 2018 |
Beshiri ML, Tice CM, Sowalsky AG, Tran C, Karzai F, Dahut W, Kelly K. Abstract 5020: A patient-derived organoid model of neuroendocrine prostate cancer transdifferentiation informing the role of the BAF complex component ARID1A Cancer Research. 78: 5020-5020. DOI: 10.1158/1538-7445.Am2018-5020 |
0.501 |
|
| 2018 |
Byun JS, Yan T, Sowalsky A, Zhu J, Meltzer P, Vohra N, Kragel P, Napoles A, Perez-Stable E, Gardner K. Abstract 4246: Characterizing breast cancer health disparities through molecular and genomic profiling of a diverse breast cancer cohort Cancer Research. 78: 4246-4246. DOI: 10.1158/1538-7445.Am2018-4246 |
0.31 |
|
| 2017 |
Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky AG, Rodriguez-Nieves J, Vander Griend D, Paner G, VanderWeele D. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European Urology Focus. PMID 29229583 DOI: 10.1016/J.Euf.2017.12.003 |
0.48 |
|
| 2017 |
Sowalsky AG, Kissick HT, Gerrin S, Schaefer R, Xia Z, Russo J, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP. Gleason Score 7 Prostate Cancers Emerge Through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28119368 DOI: 10.1158/1078-0432.Ccr-16-2414 |
0.461 |
|
| 2017 |
Sowalsky AG, Ye H, Schaefer RJ, Voznesensky OS, Zhang Z, Lis R, Bubley GJ, Taplin M, Balk SP. Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer. Journal of Clinical Oncology. 35: 98-98. DOI: 10.1200/Jco.2017.35.6_Suppl.98 |
0.396 |
|
| 2017 |
Hennigan S, Trostel S, Sowalsky AG. Abstract LB-275: Precise enumeration of cell-free DNA from patient-derived cell lines Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-275 |
0.378 |
|
| 2017 |
Beshiri ML, Tran C, Sowalsky AG, Nguyen HM, Agarwal S, Tice CM, Corey E, Kelly K. Abstract 4838: Optimization of prostate cancer organoid culture methods to grow PDX and human biopsy tissue Cancer Research. 77: 4838-4838. DOI: 10.1158/1538-7445.Am2017-4838 |
0.435 |
|
| 2016 |
VanderWeele DJ, Turkbey B, Sowalsky AG. PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Review of Precision Medicine and Drug Development. 1: 505-515. PMID 28133630 DOI: 10.1080/23808993.2016.1267562 |
0.391 |
|
| 2016 |
Gerrin SJ, Sowalsky AG, Balk SP, Ye H. Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma. The Prostate. PMID 27272561 DOI: 10.1002/Pros.23212 |
0.461 |
|
| 2016 |
Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. The Journal of Clinical Investigation. PMID 27043282 DOI: 10.1172/Jci78815 |
0.5 |
|
| 2016 |
Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, et al. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26936914 DOI: 10.1158/1078-0432.Ccr-15-2309 |
0.489 |
|
| 2015 |
Kumar S, Lu B, Dixit U, Hossain S, Liu Y, Li J, Hornbeck P, Zheng W, Sowalsky AG, Kotula L, Birge RB. Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma. Oncotarget. PMID 26473374 DOI: 10.18632/Oncotarget.6096 |
0.396 |
|
| 2015 |
Sowalsky AG, Sager R, Schaefer RJ, Bratslavsky G, Pandolfi PP, Balk SP, Kotula L. Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget. 6: 12383-91. PMID 25906751 DOI: 10.18632/Oncotarget.3564 |
0.499 |
|
| 2015 |
Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1273-80. PMID 25320358 DOI: 10.1158/1078-0432.Ccr-14-1220 |
0.467 |
|
| 2015 |
Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Molecular Cancer Research : McR. 13: 98-106. PMID 25189356 DOI: 10.1158/1541-7786.Mcr-14-0273 |
0.49 |
|
| 2014 |
Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1590-600. PMID 24449822 DOI: 10.1158/1078-0432.Ccr-13-1863 |
0.493 |
|
| 2013 |
Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. The Journal of Clinical Investigation. 123: 1109-22. PMID 23426182 DOI: 10.1172/Jci66666 |
0.523 |
|
| 2013 |
Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Research. 73: 1050-5. PMID 23204237 DOI: 10.1158/0008-5472.Can-12-2799 |
0.41 |
|
| 2011 |
Alt-Holland A, Sowalsky AG, Szwec-Levin Y, Shamis Y, Hatch H, Feig LA, Garlick JA. Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src. The Journal of Investigative Dermatology. 131: 2306-15. PMID 21716326 DOI: 10.1038/Jid.2011.188 |
0.638 |
|
| 2011 |
Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA. RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin. Cancer Research. 71: 758-67. PMID 21159665 DOI: 10.1158/0008-5472.Can-10-2756 |
0.625 |
|
| 2010 |
Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA. RalA suppresses early stages of Ras-induced squamous cell carcinoma progression. Oncogene. 29: 45-55. PMID 19802010 DOI: 10.1038/Onc.2009.307 |
0.588 |
|
| 2009 |
Alt‐Holland A, Sowalsky AG, Szwec‐Levin Y, Shamis Y, Feig LA, Garlick JA. Abstract C254: Suppression of E‐cadherin function leads to deregulation of FAK and Src to direct squamous cell carcinoma progression Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C254 |
0.646 |
|
| Show low-probability matches. |